Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:DNTH NASDAQ:GMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$238.59+4.6%$232.03$160.86▼$250.74$14.22B0.39603,126 shs836,578 shsBBIOBridgeBio Pharma$68.63-0.4%$69.37$41.80▼$84.94$13.50B0.972.72 million shs2.45 million shsDNTHDianthus Therapeutics$87.53+0.2%$86.51$17.10▼$96.50$4.78B1.181.09 million shs969,216 shsGMABGenmab A/S$25.94+1.3%$26.39$20.23▼$35.43$15.97B0.851.57 million shs1.26 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-1.23%+2.11%-7.71%+5.78%+28.89%BBIOBridgeBio Pharma+4.00%+1.35%-0.29%+0.57%+65.16%DNTHDianthus Therapeutics+5.92%+5.89%+1.03%+11.23%+418.52%GMABGenmab A/S+1.35%+4.19%-4.69%-0.77%+21.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$238.59+4.6%$232.03$160.86▼$250.74$14.22B0.39603,126 shs836,578 shsBBIOBridgeBio Pharma$68.63-0.4%$69.37$41.80▼$84.94$13.50B0.972.72 million shs2.45 million shsDNTHDianthus Therapeutics$87.53+0.2%$86.51$17.10▼$96.50$4.78B1.181.09 million shs969,216 shsGMABGenmab A/S$25.94+1.3%$26.39$20.23▼$35.43$15.97B0.851.57 million shs1.26 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-1.23%+2.11%-7.71%+5.78%+28.89%BBIOBridgeBio Pharma+4.00%+1.35%-0.29%+0.57%+65.16%DNTHDianthus Therapeutics+5.92%+5.89%+1.03%+11.23%+418.52%GMABGenmab A/S+1.35%+4.19%-4.69%-0.77%+21.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3923.81% UpsideBBIOBridgeBio Pharma 2.84Moderate Buy$91.0532.66% UpsideDNTHDianthus Therapeutics 2.93Moderate Buy$117.8234.60% UpsideGMABGenmab A/S 2.75Moderate Buy$37.9346.22% UpsideCurrent Analyst Ratings BreakdownLatest DNTH, GMAB, ASND, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026GMABGenmab A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.006/16/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$106.00 ➝ $96.006/10/2026DNTHDianthus Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026DNTHDianthus Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026DNTHDianthus Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy6/10/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.005/27/2026GMABGenmab A/S Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M18.27N/AN/A($2.97) per share-80.33BBIOBridgeBio Pharma$502.08M26.77N/AN/A($10.77) per share-6.37DNTHDianthus Therapeutics$2.04M2,345.72N/AN/A$11.41 per share7.67GMABGenmab A/S$3.90B4.15$1.63 per share15.91$9.10 per share2.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6727.5222.15N/A57.87%N/A-8.37%8/6/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A527.92N/A-124.42%N/A-65.81%8/4/2026 (Estimated)DNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%8/6/2026 (Estimated)GMABGenmab A/S$963M$1.3219.6515.441.5221.05%15.34%8.94%8/6/2026 (Estimated)Latest DNTH, GMAB, ASND, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/5/2026Q1 2026DNTHDianthus Therapeutics-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BBIOBridgeBio PharmaN/A1.521.48DNTHDianthus TherapeuticsN/A29.2529.25GMABGenmab A/S0.872.182.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%DNTHDianthus Therapeutics47.53%GMABGenmab A/S7.07%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%DNTHDianthus Therapeutics3.02%GMABGenmab A/S1.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableDNTHDianthus Therapeutics8054.67 million53.02 millionOptionableGMABGenmab A/S3,029623.53 million613.93 millionOptionableDNTH, GMAB, ASND, and BBIO HeadlinesRecent News About These CompaniesGenmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 23 at 3:19 AM | americanbankingnews.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseJune 16, 2026 | globenewswire.comGenmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh UpsideJune 15, 2026 | finance.yahoo.comGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)June 13, 2026 | globenewswire.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJune 11, 2026 | globenewswire.comGenmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PatientsJune 11, 2026 | globenewswire.comGenmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLYJune 4, 2026 | theglobeandmail.comWells Fargo Gives a Buy Rating to Genmab (GMAB)June 3, 2026 | theglobeandmail.comTransactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsMay 29, 2026 | globenewswire.comGenmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 CongressMay 21, 2026 | globenewswire.comGenmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation EstimateMay 17, 2026 | finance.yahoo.comGenmab A/S (GMAB) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comGenmab A/S: Capital Increase in Genmab as a Result of Employee Warrant ExerciseMay 13, 2026 | finanznachrichten.de5 Most Promising Biotech Stocks to Buy NowMay 12, 2026 | insidermonkey.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 12, 2026 | globenewswire.comGenmab A/S 2026 Q1 - Results - Earnings Call PresentationMay 10, 2026 | seekingalpha.comIs It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share PerformanceMay 8, 2026 | finance.yahoo.comGenmab Announces Financial Results for the First Quarter of 2026May 7, 2026 | globenewswire.comWhat To Expect From Genmab AS (GMAB) Q1 2026 EarningsMay 6, 2026 | finance.yahoo.comGenmab (GMAB) Rated Outperform on Oncology PipelineMay 3, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNTH, GMAB, ASND, and BBIO Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$238.59 +10.59 (+4.64%) Closing price 04:00 PM EasternExtended Trading$238.26 -0.34 (-0.14%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$68.63 -0.29 (-0.42%) Closing price 04:00 PM EasternExtended Trading$68.99 +0.36 (+0.53%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Dianthus Therapeutics NASDAQ:DNTH$87.53 +0.16 (+0.18%) Closing price 04:00 PM EasternExtended Trading$87.48 -0.06 (-0.06%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Genmab A/S NASDAQ:GMAB$25.94 +0.33 (+1.29%) Closing price 04:00 PM EasternExtended Trading$25.94 0.00 (0.00%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
